Try our beta test site
45 studies found for:    "Anthrax"
Show Display Options
Rank Status Study
21 Completed Trial of rPA-102 Vaccine in Healthy Adult Volunteers
Condition: Anthrax
Intervention: Biological: rPA102
22 Not yet recruiting An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis
Conditions: Infection, Bacterial;   Anthrax
Interventions: Other: Collection of samples;   Biological: Obiltoxaximab
23 Completed
Has Results
Ciprofloxacin BioThrax Co-Administration Study
Condition: Anthrax
Interventions: Biological: BioThrax;   Drug: Ciprofloxacin
24 Completed
Has Results
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Condition: Anthrax
Intervention: Biological: BioThrax
25 Completed Placebo-Controlled, Sequential Group, Single Dose, Dose-Escalation Study to Evaluate the Safety and PK of ETI-204
Condition: Anthrax
Interventions: Drug: ETI-204, "Anthim";   Drug: placebo
26 Completed Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Condition: Anthrax
Interventions: Drug: Normal Saline for Injection;   Biological: MDX1303
27 Completed Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Condition: Anthrax
Interventions: Drug: AVP-21D9;   Drug: Placebo
28 Terminated Ph1 Study of Valortim and Doxycycline in Humans
Condition: Anthrax
Interventions: Drug: Doxycycline and Valortim;   Drug: Placebo Antibiotic and Valortim;   Drug: Placebo Antibiotic and Placebo Valortim
29 Suspended Ph1 Study of Valortim and Ciprofloxacin in Humans
Condition: Anthrax
Interventions: Drug: Ciprofloxacin and Valortim;   Drug: Placebo Antibiotic and Valortim;   Other: Placebo Antibiotic and Placebo Valortim
30 Completed Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Other: IV Ciprofloxacin;   Other: Oral Ciprofloxacin
31 Completed Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
32 Completed Safety, Tolerability and PK of Repeat Administration of IV ETI-204
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
33 Completed A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers
Condition: Inhalational Anthrax
Interventions: Biological: ETI-204;   Biological: Placebo
34 Completed CDC Anthrax Vaccine Clinical Trial
Condition: Healthy
Intervention: Biological: BioThrax or Anthrax Vaccine Adsorbed
35 Completed
Has Results
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Condition: Therapeutic Treatment of Inhalation Anthrax
Intervention: Biological: Raxibacumab
36 Active, not recruiting Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Condition: Infections, Bacterial
Interventions: Biological: AVA;   Biological: Raxibacumab;   Drug: Diphenhydramine
37 Active, not recruiting Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
Conditions: Ischemic Stroke;   Malignant Edema
Intervention: Drug: RP-1127 (Glyburide for Injection)
38 Recruiting BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Conditions: Pregnancy Complications;   Pregnancy Outcome;   Congenital Abnormalities
Intervention: Biological: Observational Intervention
39 Completed VHA Clinicians and Bioterror Events: Interactive Web-based Learning
Conditions: Smallpox;   Anthrax
Intervention: Behavioral: BioCASES and BioTESTS
40 Recruiting Special Drug Use Investigation of Ciproxan Injection in Pediatrics
Condition: Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Intervention: Drug: Cipro (Ciprofloxacin, BAYQ3939)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.